Related Experiment Video
Updated: May 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Immunophenotypic aberrancies in molecularly confirmed acute promyelocytic leukemia: lessons from two cases
Lumen Agarkar Prattipati1, Rakhee Kar2, Arvind Kumar Gupta3
1Department of Pathology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India.
Abstract:
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by PML::RARA fusion, typical morphology, and a characteristic flow cytometric immunophenotype that enables rapid diagnosis. However, immunophenotypic aberrancies may occur and can mimic mixed phenotype acute leukemia (MPAL), leading to diagnostic and therapeutic dilemmas. We report two adult male patients with APL confirmed by fluorescence in situ hybridization (FISH) demonstrating PML::RARA fusion. Both cases exhibited unusual immunophenotype. In the first case, peripheral blood flow cytometry revealed blasts with bright cMPO, CD34, dim HLA-DR, along with aberrant expression of CD19 (moderate), cCD79a (dim), cCD3 (heterogeneous), and CD7, raising a suspicion for MPAL. However, lineage defining criteria for T- and B-lineages were not fulfilled. Marrow showed abnormal promyelocytes with bundles of Auer rods, and molecular studies confirmed APL. In the second case, morphology suggested microgranular variant APL. Flow cytometry demonstrated aberrant expression of lymphoid and monocytic markers, including CD19 (dim), sCD3 (moderate), CD7, and CD14 (moderate), in addition to cMPO. Cytogenetics and molecular studies confirmed t(15;17)/PML::RARA in both cases, along with FLT3-ITD mutations. One patient developed differentiation syndrome and responded to all-trans-retinoic acid, while the follow-up of the second patient is unavailable. APL may exhibit immunophenotypic aberrancies mimicking MPAL. Molecular confirmation of PML::RARA and an integrated diagnostic approach are essential to avoid misclassification and ensure timely therapy.
Insights
Acute promyelocytic leukemia (APL) can present with unusual immunophenotypes mimicking mixed phenotype acute leukemia (MPAL). Molecular confirmation of PML::RARA fusion is crucial for accurate diagnosis and timely treatment of APL.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia.
- APL diagnosis typically relies on morphology and flow cytometry.
- Immunophenotypic aberrancies in APL can mimic other leukemias like MPAL.
Purpose of the Study:
- To report cases of APL with unusual immunophenotypes.
- To highlight diagnostic challenges posed by aberrant APL immunophenotypes.
- To emphasize the importance of molecular confirmation in APL diagnosis.
Main Methods:
- Case report of two adult male patients with APL.
- Flow cytometry and immunophenotyping.
- Fluorescence in situ hybridization (FISH) for PML::RARA fusion.
- Cytogenetics and molecular studies (including FLT3-ITD).
Main Results:
- Both patients had APL confirmed by FISH for PML::RARA.
- Both cases exhibited aberrant immunophenotypes with lymphoid and monocytic markers.
- Morphology and molecular studies confirmed APL despite immunophenotypic mimicry of MPAL.
Conclusions:
- APL can display immunophenotypic aberrancies that mimic MPAL.
- Integrated diagnostic approaches combining morphology, immunophenotyping, and molecular studies are essential.
- Accurate diagnosis of APL is critical for appropriate and timely therapy, such as all-trans-retinoic acid.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation